Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in Gbrca1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Patricia A. Ganz , Hanna Bandos , Tanja Spanic , Sue Friedman , Volkmar Mueller , Sherko Kuemmel , Suzette Delaloge , Etienne Brain , Masakazu Toi , Hideko Yamauchi , Eduardo-M. de Duenas , Anne Armstrong , Seock-Ah Im , Chuan-gui Song , Hong Zheng , Tomasz Sarosiek , Priyanka Sharma , Cuizhi Geng , Peifen Fu , Kerstin Rhiem , Heike Frauchiger-Heuer , Pauline Wimberger , Daphne t'Kint de Roodenbeke , Ning Liao , Annabel Goodwin , Camille Chakiba-Brugere , Michael Friedlander , Keun Seok Lee , Sylvie Giacchetti , Toshimi Takano , Fernando Henao-Carrasco , Shamsuddin Virani , Frances Valdes-Albini , Susan M. Domchek , Charles Bane , Edward C. Mccarron , Monica Mita , Giovanna Rossi , Priya Rastogi , Anitra Fielding , Richard D. Gelber , Elsemieke D. Scheepers , David Cameron , Judy Garber , Charles E. Geyer , Andrew N. J. Tutt Journal of Clinical Oncology（2024）
AI 理解论文
溯源树
样例
